Compare Amylx Pharmaceuticals Inc (AMLX) vs Chubb Ltd (CB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Chubb Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Chubb Ltd trades at $347.09 (market cap $134.37B). The key difference: Chubb Ltd is far larger — about 53.1× Amylx Pharmaceuticals Inc's market cap, and Chubb Ltd pays a 1.17% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CB | |
|---|---|---|
Market Cap | $2.53B | $134.37B |
Sector | Health | Financials |
52-Week High | $24.19 | $363.50 |
52-Week Low | $7.82 | $268.20 |
Enterprise Value | $2.28B | $155.22B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Chubb (CB) trades at $350.31, down 1.05% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $7.26 beating estimates, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Recent news highlights leadership appointments and positive earnings coverage.
The outlook is positive, supported by consistent earnings beats, a 52.38% analyst buy rating, and a consensus price target of $366.83. Risks include macroeconomic sensitivity and competitive pressures in insurance. The stock presents a value opportunity with a P/E of 12.41 and robust cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
